ClinicalTrials.gg

Program

STEAP2-targeting Radioconjugate AZD2287

Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.

Furthest: phase 2, since Jan 5, 20242 company-led studies, 2 open or runningNext primary completion: Nov 24, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 2since Jan 5, 2024Jan 5, 2024Nov 24, 2026phase 2 · NCT06267729

Also a collaborator on its studies: Parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 5, 2024First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06267729 · 60 planned · United States, Australia, Spain
  2. Mar 11, 2025Phase 1 study in Prostatic NeoplasmsNCT06879041 · 136 planned · United States, Australia, South Africa

Ahead

  1. Nov 24, 2026Primary completion: phase 2 study in Prostatic NeoplasmsNCT06267729
  2. Apr 16, 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT06879041

TargetBeta

STEAP2 →read by rule
“A radioconjugate targeting the tumor-associated antigen (TAA) metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1) ”NCIt, by rule

Other programs on STEAP2

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06879041Prostatic Neoplasms · United States, Australia, South Africa1RecruitingApr 16, 2029136
NCT06267729Prostatic Neoplasms · United States, Australia, Spain2RecruitingNov 24, 202660

How it is read

Names in the registry

  • “AZD2287”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.